Amphastar Pharmaceuticals Inc. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 170.5M
Gross Profit 85.3M 49.99%
Operating Income 37.3M 21.87%
Net Income 25.3M 14.83%
EPS (Diluted) $0.51

Balance Sheet Metrics

Total Assets 1.6B
Total Liabilities 875.0M
Shareholders Equity 751.3M
Debt to Equity 1.16

Cash Flow Metrics

Operating Cash Flow 16.2M
Free Cash Flow 24.4M

Revenue & Profitability Trend

Amphastar Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i732.0M644.4M499.0M437.8M349.8M
Cost of Goods Sold i358.1M293.3M250.1M238.0M206.5M
Gross Profit i373.9M351.1M248.9M199.7M143.3M
Gross Margin % i51.1%54.5%49.9%45.6%41.0%
Operating Expenses
Research & Development i73.9M73.7M74.8M60.9M67.2M
Selling, General & Administrative i94.5M80.4M66.6M68.9M65.2M
Other Operating Expenses i-----
Total Operating Expenses i168.4M154.1M141.4M129.9M132.4M
Operating Income i205.4M197.0M107.5M69.9M11.0M
Operating Margin % i28.1%30.6%21.5%16.0%3.1%
Non-Operating Items
Interest Income i10.6M5.5M1.3M601.0K642.0K
Interest Expense i30.3M27.2M1.8M885.0K374.0K
Other Non-Operating Income4.1M-3.9M9.1M14.5M-6.6M
Pre-tax Income i189.8M171.4M116.0M84.1M4.6M
Income Tax i29.7M31.8M23.5M20.6M3.5M
Effective Tax Rate % i15.6%18.6%20.2%24.5%76.3%
Net Income i159.5M137.5M91.4M63.3M1.1M
Net Margin % i21.8%21.3%18.3%14.5%0.3%
Key Metrics
EBITDA i277.3M240.3M146.2M111.6M30.2M
EPS (Basic) i$3.29$2.85$1.88$1.30$0.03
EPS (Diluted) i$3.06$2.60$1.74$1.25$0.03
Basic Shares Outstanding i4842900048265000485510004777700047038000
Diluted Shares Outstanding i4842900048265000485510004777700047038000

Income Statement Trend

Amphastar Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i151.6M144.3M156.1M126.4M92.6M
Short-term Investments i70.0M112.5M19.7M10.3M13.0M
Accounts Receivable i136.3M114.9M88.8M78.8M66.0M
Inventory i153.7M105.8M103.6M92.8M96.8M
Other Current Assets18.2M9.1M7.6M7.3M6.8M
Total Current Assets i534.1M489.6M378.3M318.1M279.7M
Non-Current Assets
Property, Plant & Equipment i47.3M32.9M26.3M27.2M20.7M
Goodwill i593.7M616.5M40.4M42.2M44.6M
Intangible Assets i587.6M610.1M34.2M35.6M36.7M
Long-term Investments-----
Other Non-Current Assets97.1M79.2M59.4M39.1M30.2M
Total Non-Current Assets i1.0B1.0B363.7M353.4M351.6M
Total Assets i1.6B1.5B742.0M671.5M631.2M
Liabilities
Current Liabilities
Accounts Payable i30.5M25.4M20.5M22.2M24.4M
Short-term Debt i7.0M4.3M6.0M5.2M15.6M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i173.8M225.4M94.9M103.8M112.2M
Non-Current Liabilities
Long-term Debt i643.5M619.3M96.5M99.5M51.6M
Deferred Tax Liabilities i7.0M6.1M7.4M7.1M5.4M
Other Non-Current Liabilities20.9M22.7M14.6M15.7M13.2M
Total Non-Current Liabilities i671.4M648.1M118.5M122.2M70.3M
Total Liabilities i845.2M873.5M213.3M226.0M182.5M
Equity
Common Stock i6.0K6.0K6.0K6.0K5.0K
Retained Earnings i568.8M409.3M271.7M180.3M117.8M
Treasury Stock i332.7M247.4M189.5M150.5M121.8M
Other Equity-----
Total Shareholders Equity i732.3M639.4M528.7M445.5M448.7M
Key Metrics
Total Debt i650.5M623.6M102.6M104.7M67.3M
Working Capital i360.3M264.2M283.5M214.3M167.5M

Balance Sheet Composition

Amphastar Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i159.5M137.5M91.4M63.3M1.1M
Depreciation & Amortization i57.2M41.8M28.3M26.5M25.2M
Stock-Based Compensation i24.4M20.2M17.9M18.7M20.5M
Working Capital Changes i-3.8M-21.5M-30.3M-4.9M10.7M
Operating Cash Flow i226.3M175.7M91.9M108.1M58.6M
Investing Activities
Capital Expenditures i-41.0M-38.2M-23.6M-27.5M-33.9M
Acquisitions i-129.0M-506.4M00-
Investment Purchases i-76.8M-144.6M-35.8M-17.4M-13.6M
Investment Sales i126.0M38.6M28.0M18.8M12.4M
Investing Cash Flow i-124.9M-649.1M-32.8M-28.7M-36.4M
Financing Activities
Share Repurchases i-85.5M-58.1M-39.9M-28.9M-24.4M
Dividends Paid i-----
Debt Issuance i18.4M845.0M070.0M6.3M
Debt Repayment i-8.3M-318.7M-1.8M-37.9M-8.4M
Financing Cash Flow i-76.1M443.1M-42.1M-54.1M-25.4M
Free Cash Flow i172.3M145.3M65.1M70.5M23.4M
Net Change in Cash i25.3M-30.3M17.0M25.3M-3.3M

Cash Flow Trend

Amphastar Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 7.72
Forward P/E 4.87
Price to Book 1.35
Price to Sales 1.37
PEG Ratio 4.87

Profitability Ratios

Profit Margin 19.38%
Operating Margin 21.87%
Return on Equity 19.90%
Return on Assets 7.60%

Financial Health

Current Ratio 2.95
Debt to Equity 86.86
Beta 0.76

Per Share Data

EPS (TTM) $2.76
Book Value per Share $15.76
Revenue per Share $15.13

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
amph1.0B7.721.3519.90%19.38%86.86
Zoetis 67.7B27.3114.5852.09%27.12%145.63
Haleon Plc - ADR 43.4B21.955.459.38%13.81%53.41
BioCryst 1.8B-19.41-4.1518.68%-6.41%-1.97
BGM 1.6B15.004.42-16.52%-26.32%0.22
Ani Pharmaceuticals 1.5B51.633.31-4.57%-3.12%142.03

Financial data is updated regularly. All figures are in the company's reporting currency.